Antineoplastic agents. 465. Structural modification of resveratrol: sodium resverastatin phosphate

  • J Med Chem. 2002 Jun 6;45(12):2534-42. doi: 10.1021/jm010119y.
George R Pettit  1 ,  Matthew P Grealish ,  M Katherine Jung ,  Ernest Hamel ,  Robin K Pettit ,  J-Charles Chapuis ,  Jean M Schmidt
Affiliations
  • 1. Department of Chemistry and Biochemistry, Cancer Research Institute, Arizona State University, P.O. Box 872404, Tempe, AZ 85287-2404, USA. [email protected]
PMID: 12036362 DOI: 10.1021/jm010119y
Abstract

As an extension of structure/activity investigations of resveratrol (1), phenstatin (2c), and the Cancer antiangiogenesis drug sodium combretastatin A-4 phosphate (2b), syntheses of certain related Stilbenes (14) and benzophenones (16) were undertaken. The trimethyl ether derivative of (Z)-resveratrol (4a) exhibited the strongest activity (GI(50) = 0.01-0.001 microg/mL) against a minipanel of human Cancer cell lines. A monodemethylated derivative (14c) was converted to prodrug 14n (sodium resverastatin phosphate) for further biological evaluation. The antitubulin and antimicrobial activities of selected compounds were also evaluated.